Target Pipelines
Showing 41–50 of 50 results
- May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- April of 2020This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00
- February of 2020This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- September of 2019This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.€ 250.00
- July of 2019This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- June of 2019This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.€ 50.00
- May of 2019This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)€ 150.00
- April of 2019This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.€ 50.00
- December of 2018This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.€ 75.00
- January of 2019This Target Pipeline List provides an overview of agonist antibodies and fusion proteins targeting death receptor 4 and/or 5 in development for treatment of cancer.€ 100.00